Henry Schein Elects Reed V. Tuckson, M.D., FACP to Board of Directors
May 17 2021 - 8:05AM
Business Wire
Innovative Health Care Leader Brings
Background in Comprehensive, Multi-Disciplinary, and Integrated
Health Care to the Company
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider
of health care solutions to office-based dental and medical
practitioners, today announced the election of Reed V. Tuckson,
M.D., FACP, to the Company’s Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210517005408/en/
Reed V. Tuckson, M.D., FACP (Photo:
Business Wire)
Dr. Tuckson brings a wealth of health care experience to the
Henry Schein Board. Since 2014, he has served as Managing Director
of Tuckson Health Connections, LLC, a health and medical care
consulting business that brings people and ideas together to
promote optimal health outcomes and value through innovation and
integration. Dr. Tuckson is also the Founder of the Black Coalition
Against COVID-19, a community-based initiative that seeks to
provide trustworthy, science-based, information curated for the
Black community and other communities of color about COVID-19
vaccines and related topics in an effort to help save lives.
Previously, Dr. Tuckson served as Executive Vice President and
Chief of Medical Affairs for UnitedHealth Group, where he oversaw
the company’s medical and clinical-related policies and activities.
Dr. Tuckson has also held positions as Senior Vice President,
Professional Standards of the American Medical Association;
President of the Charles R. Drew University of Medicine and Science
in Los Angeles, California; Senior Vice President for Programs of
the March of Dimes Birth Defects Foundation; and Commissioner of
Public Health for the District of Columbia.
“We are delighted to welcome Dr. Tuckson to the Henry Schein
Board of Directors,” said Stanley M. Bergman, Chairman and Chief
Executive Officer for Henry Schein. “Having worked for more than 35
years in nearly every sector of the health and medical care
industries, Dr. Tuckson is a well-respected and innovative health
care leader who is deeply skilled at bringing together a variety of
stakeholder groups to catalyze change. We look forward to the
valuable perspective Dr. Tuckson will bring as we continue on our
path to advance health equity, drive innovation, and serve our
customers whose needs are rapidly evolving.”
Dr. Tuckson has been a member of numerous federal advisory
committees and corporate, non-profit, and academic boards.
Currently, he serves on the board of directors of CTI BioPharma
Corp., a public company that develops cancer pharmaceuticals, and
Adverum Biotechnologies, Inc., a clinical-stage gene therapy
company targeting unmet medical needs in ocular and rare diseases.
Dr. Tuckson is also a member of the board of trustees of Howard
University, where he serves as Chair of the Health Sciences
Committee, and is a member of the advisory board of the National
Institutes of Health Clinical Center and serves on several
committees of the National Academy of Medicine.
“I’m honored to join this distinguished Board and have
long-admired the Company’s commitment to a purpose-driven,
values-based culture that balances the needs of all stakeholders,”
said Dr. Tuckson. “I look forward to joining my fellow board
members to advance Henry Schein’s impressive commitment to a
socially responsible future that includes addressing racial
disparities in health access and outcomes while providing health
care practitioners with the solutions needed to meet the global
demand for quality patient care.”
Dr. Tuckson received a B.S. from Howard University and an M.D.
from Georgetown University School of Medicine. Dr. Tuckson
completed the University of Pennsylvania Hospital’s General
Internal Medicine Residency and Fellowship programs, where he was
also a Robert Wood Johnson Foundation Clinical Scholar studying at
the Wharton School of Business.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for
health care professionals powered by a network of people and
technology. With more than 20,000 Team Schein Members worldwide,
the Company's network of trusted advisors provides more than 1
million customers globally with more than 300 valued solutions that
help improve operational success and clinical outcomes. Our
Business, Clinical, Technology, and Supply Chain solutions help
office-based dental and medical practitioners work more efficiently
so they can provide quality care more effectively. These solutions
also support dental laboratories, government and institutional
health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 120,000 branded
products and Henry Schein private-brand products in stock, as well
as more than 180,000 additional products available as special-order
items.
A FORTUNE 500 Company and a member of the S&P 500® index,
Henry Schein is headquartered in Melville, N.Y., and has operations
or affiliates in 31 countries and territories. The Company's sales
reached $10.1 billion in 2020, and have grown at a compound annual
rate of approximately 12 percent since Henry Schein became a public
company in 1995.
For more information, visit Henry Schein at www.henryschein.com,
Facebook.com/HenrySchein, and @HenrySchein on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210517005408/en/
Ann Marie Gothard, Vice President, Corporate Media Relations,
annmarie.gothard@henryschein.com (631) 390-8169
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Apr 2023 to Apr 2024